These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 21903504)

  • 1. Increased serum lactate dehydrongenase should be included among the variables that define very-high-risk multiple myeloma.
    Gkotzamanidou M; Kastritis E; Gavriatopoulou MR; Nikitas N; Gika D; Mparmparousi D; Matsouka C; Terpos E; Dimopoulos MA
    Clin Lymphoma Myeloma Leuk; 2011 Oct; 11(5):409-13. PubMed ID: 21903504
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High serum lactate dehydrogenase adds prognostic value to the international myeloma staging system even in the era of novel agents.
    Terpos E; Katodritou E; Roussou M; Pouli A; Michalis E; Delimpasi S; Parcharidou A; Kartasis Z; Zomas A; Symeonidis A; Viniou NA; Anagnostopoulos N; Economopoulos T; Zervas K; Dimopoulos MA;
    Eur J Haematol; 2010 Aug; 85(2):114-9. PubMed ID: 20477863
    [TBL] [Abstract][Full Text] [Related]  

  • 3. LDH is an adverse prognostic factor independent of ISS in transplant-eligible myeloma patients receiving bortezomib-based induction regimens.
    Chim CS; Sim J; Tam S; Tse E; Lie AK; Kwong YL
    Eur J Haematol; 2015 Apr; 94(4):330-5. PubMed ID: 25135740
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Re-evaluation of prognostic markers including staging, serum free light chains or their ratio and serum lactate dehydrogenase in multiple myeloma patients receiving novel agents.
    Maltezas D; Dimopoulos MA; Katodritou I; Repousis P; Pouli A; Terpos E; Panayiotidis P; Delimpasi S; Michalis E; Anargyrou K; Gavriatopoulou M; Stefanoudaki A; Tzenou T; Koulieris E; Sachanas S; Dimou M; Vassilakopoulos TP; Angelopoulou MK; Pangalis GA; Kyrtsonis MC
    Hematol Oncol; 2013 Jun; 31(2):96-102. PubMed ID: 22961993
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High serum lactate dehydrogenase predicts an unfavorable outcome in Chinese elderly patients with multiple myeloma.
    Gu Y; Yuan YH; Xu J; Shi QL; Qu XY; Guo R; Bai H; Xu JD; Li JY; Chen LJ
    Oncotarget; 2017 Jul; 8(29):48350-48361. PubMed ID: 28418851
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High serum lactate dehydrogenase level as a marker for drug resistance and short survival in multiple myeloma.
    Dimopoulos MA; Barlogie B; Smith TL; Alexanian R
    Ann Intern Med; 1991 Dec; 115(12):931-5. PubMed ID: 1952489
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multiple myeloma in elderly patients: prognostic factors and outcome.
    Anagnostopoulos A; Gika D; Symeonidis A; Zervas K; Pouli A; Repoussis P; Grigoraki V; Anagnostopoulos N; Economopoulos T; Maniatis A; Dimopoulos MA
    Eur J Haematol; 2005 Nov; 75(5):370-5. PubMed ID: 16191085
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Revised International Staging System Applied to Real World Multiple Myeloma Patients.
    Jimenez-Zepeda VH; Duggan P; Neri P; Rashid-Kolvear F; Tay J; Bahlis NJ
    Clin Lymphoma Myeloma Leuk; 2016 Sep; 16(9):511-518. PubMed ID: 27425179
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Erythropoiesis-stimulating agents are associated with reduced survival in patients with multiple myeloma.
    Katodritou E; Verrou E; Hadjiaggelidou C; Gastari V; Laschos K; Kontovinis L; Kapetanos D; Constantinou N; Terpos E; Zervas K
    Am J Hematol; 2008 Sep; 83(9):697-701. PubMed ID: 18626886
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multiple myeloma in octogenarians: clinical features and outcome in the novel agent era.
    Dimopoulos MA; Kastritis E; Delimpasi S; Katodritou E; Hatzimichael E; Kyrtsonis MC; Repousis P; Tsirogianni M; Kartasis Z; Parcharidou A; Michael M; Michalis E; Tsatalas C; Stefanoudaki E; Hatjiharissi E; Gika D; Symeonidis A; Terpos E; Zervas K;
    Eur J Haematol; 2012 Jul; 89(1):10-5. PubMed ID: 22469521
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The significance of lactate dehydrogenase and beta 2-microglobulin levels for the assessment of the prognosis and choice of therapy in multiple myeloma].
    Iakovleva SV; Andreeva NE; Izgorodin AS
    Ter Arkh; 1995; 67(7):35-9. PubMed ID: 7482303
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High serum lactate dehydrogenase level predicts short survival after vincristine-doxorubicin-dexamethasone (VAD) salvage for refractory multiple myeloma.
    Suguro M; Kanda Y; Yamamoto R; Chizuka A; Hamaki T; Matsuyama T; Takezako N; Miwa A; Togawa A
    Am J Hematol; 2000 Oct; 65(2):132-5. PubMed ID: 10996830
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Chronic Kidney Disease Epidemiology Collaboration cystatin C (CKD-EPI-CysC) equation has an independent prognostic value for overall survival in newly diagnosed patients with symptomatic multiple myeloma; is it time to change from MDRD to CKD-EPI-CysC equations?
    Terpos E; Christoulas D; Kastritis E; Katodritou E; Pouli A; Michalis E; Papassotiriou I; Dimopoulos MA;
    Eur J Haematol; 2013 Oct; 91(4):347-55. PubMed ID: 23829647
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A new staging system to predict prognosis of patients with multiple myeloma in an era of novel therapeutic agents.
    Iriuchishima H; Saitoh T; Handa H; Isoda A; Matsumoto M; Sawamura M; Iwasaki A; Ushie C; Hattori H; Sasaki Y; Mitsui T; Yokohama A; Tsukamoto N; Murakami H; Nojima Y
    Eur J Haematol; 2015 Feb; 94(2):145-51. PubMed ID: 24981274
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hypercalcemia remains an adverse prognostic factor for newly diagnosed multiple myeloma patients in the era of novel antimyeloma therapies.
    Zagouri F; Kastritis E; Zomas A; Terpos E; Katodritou E; Symeonidis A; Delimpasi S; Pouli A; Vassilakopoulos TP; Michalis E; Giannouli S; Kartasis Z; Christoforidou A; Kokoviadou K; Hatzimichael E; Gika D; Megalakaki C; Papaioannou M; Kyrtsonis MC; Konstantopoulos K; Dimopoulos MA;
    Eur J Haematol; 2017 Nov; 99(5):409-414. PubMed ID: 28675766
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of relapsed/refractory multiple myeloma with thalidomide-based regimens: identification of prognostic factors.
    Anagnostopoulos A; Gika D; Hamilos G; Zervas K; Zomas A; Pouli A; Zorzou M; Kastritis E; Anagnostopoulos N; Tassidou A; Anagnostou D; Dimopoulos MA
    Leuk Lymphoma; 2004 Nov; 45(11):2275-9. PubMed ID: 15512817
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum lactate dehydrogenase predicts for overall survival benefit in patients with metastatic renal cell carcinoma treated with inhibition of mammalian target of rapamycin.
    Armstrong AJ; George DJ; Halabi S
    J Clin Oncol; 2012 Sep; 30(27):3402-7. PubMed ID: 22891270
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circulating angiopoietin-1 to angiopoietin-2 ratio is an independent prognostic factor for survival in newly diagnosed patients with multiple myeloma who received therapy with novel antimyeloma agents.
    Terpos E; Anargyrou K; Katodritou E; Kastritis E; Papatheodorou A; Christoulas D; Pouli A; Michalis E; Delimpasi S; Gkotzamanidou M; Nikitas N; Koumoustiotis V; Margaritis D; Tsionos K; Stefanoudaki E; Meletis J; Zervas K; Dimopoulos MA;
    Int J Cancer; 2012 Feb; 130(3):735-42. PubMed ID: 21484787
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The highest prognostic impact of LDH among International Prognostic Indices (IPIs): an explorative study of five IPI factors among patients with DLBCL in the era of rituximab.
    Park JH; Yoon DH; Kim DY; Kim S; Seo S; Jeong Y; Lee SW; Park CS; Huh J; Suh C
    Ann Hematol; 2014 Oct; 93(10):1755-64. PubMed ID: 25027115
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group.
    Palumbo A; Avet-Loiseau H; Oliva S; Lokhorst HM; Goldschmidt H; Rosinol L; Richardson P; Caltagirone S; Lahuerta JJ; Facon T; Bringhen S; Gay F; Attal M; Passera R; Spencer A; Offidani M; Kumar S; Musto P; Lonial S; Petrucci MT; Orlowski RZ; Zamagni E; Morgan G; Dimopoulos MA; Durie BG; Anderson KC; Sonneveld P; San Miguel J; Cavo M; Rajkumar SV; Moreau P
    J Clin Oncol; 2015 Sep; 33(26):2863-9. PubMed ID: 26240224
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.